Tag: AI in Pharma
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission How pre-submission evidence reviews are becoming the next competitive advantage for pharmaceutical and biotech companies in Europe. The pharmaceutical industry has entered a new era of evidence generation. For years, achieving regulatory approval was considered the biggest milestone on the path to…
Regulatory-Grade AI and Living Evidence
Why Regulatory-Grade AI & Living Evidence Are Replacing Traditional RWE Models in Pharma A Turning Point for Real-World Evidence in Pharma Real-World Evidence (RWE) has become a cornerstone of pharmaceutical decision-making. Regulators, HTA bodies, and payers increasingly rely on RWE to support approvals, reimbursement decisions, and post-market monitoring. However, as expectations rise, traditional RWE models…
